Shares of Moderna climbed after the mRNA vaccine pioneer reported quarterly revenue that cleared Wall Street estimates. The performance suggests a stabilizing market for the company’s core technology as it looks to diversify its portfolio beyond pandemic-era products.
In section Market Quotes
Moderna Revenue Beat Lifts Health Sector Amid Sanofi CEO Shakeup
Health-care shares edged higher following a stronger-than-expected revenue report from Moderna, even as a sudden leadership transition at French drugmaker Sanofi introduced fresh volatility to the sector.
Executive Transition at Sanofi
Conversely, Sanofi is navigating internal upheaval following the abrupt replacement of Chief Executive Paul Hudson. The French pharmaceutical giant named Belén Garijo, formerly the head of German rival Merck KGaA, as his successor—a move that surprised market observers and internal stakeholders alike.The transition has drawn caution from the financial community. Analysts at Citi warned that the leadership swap exacerbates near-term uncertainty for the firm, according to a recent brokerage note. The change comes at a critical juncture for Sanofi as it attempts to streamline operations and focus on high-growth immunology treatments.
Comments (0)
No comments yet. Be the first!